Haemonetics Corporation - 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2005 (Fiscal Year 2006)
Business Overview: Designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of donor and patient blood, including single-use disposables and data management software.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 31, 2005 | 9 Months Ended Dec 31, 2005 |
|---|---|---|
| Net Revenues | $105,677 | $309,338 |
| Gross Profit | $55,669 | $161,958 |
| Gross Margin | 52.7% | 52.4% |
| Operating Income | $41,306 | $75,180 |
| Net Income | $28,089 | $51,918 |
| Diluted EPS | $1.02 | $1.89 |
| Cash and Equivalents | $229,351 | $229,351 (Balance Sheet) |
| Operating Cash Flow (9mo) | N/A | $59,493 |
| Total Debt (Current + Long-term) | $38,913 | $38,913 (Balance Sheet) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 7.7% for the quarter and 9.1% for the nine-month period compared to the prior year. Growth was driven by increases in disposable, software, and equipment revenues, partially offset by unfavorable foreign exchange impacts in the quarter.
- Profitability Surge: Operating income increased 170.0% for the quarter and 70.2% for the nine months. Net income increased 155.2% and 74.8%, respectively.
- Arbitration Award: A significant non-recurring item drove the profit increase. The company received a $30.8 million arbitration award from Baxter International in October 2005. This resulted in $26.4 million of arbitration award income recorded in operating expenses and $1.3 million in interest income.
- Expense Increases: Research and development expenses rose 43.7% (quarter) and 43.0% (nine months), primarily due to new product development and a $3.8 million impairment charge for platelet pathogen reduction technology.
- Product Mix: Red Cell disposable revenue grew 30.8% (quarter) and 31.8% (nine months), while Plasma revenue grew 13.0% (quarter). Surgical disposable revenue was relatively flat.
Guidance, Outlook, and Risks
- Outlook: Management expects the annual tax rate to be approximately 35.3% for the remainder of fiscal year 2006. The company believes current capital sources are sufficient to fund requirements for the next twelve months.
- Accounting Changes: The company is evaluating the adoption of SFAS No. 123R (Share-Based Payment), which will require fair value accounting for stock options starting in fiscal year 2007. This is expected to have a significant impact on reported results of operations.
- Foreign Exchange: Approximately 63% of sales are generated outside the U.S. (primarily Japan and Europe). The company uses forward contracts to hedge anticipated cash flows. A strengthening U.S. dollar adversely affects results, while a weakening dollar has a positive effect.
- Product Risks: The company voluntarily recalled 33 cardioPAT devices due to a check valve issue but has implemented design changes and received regulatory clearance. There is also ongoing competition in the plasma market and potential market shifts in Europe regarding pathogen reduction technology.
Investor Verification Checklist
- Non-Recurring Income: Verify the sustainability of earnings by excluding the $26.4 million Baxter arbitration award from operating income analysis.
- Impairment Charges: Review the $3.8 million impairment charge related to platelet pathogen reduction technology and its impact on R&D expenses.
- Foreign Exchange Sensitivity: Assess the impact of currency fluctuations on future margins, given that 63% of revenue is international.
- Stock-Based Compensation: Monitor the transition to SFAS No. 123R in fiscal 2007, which will likely reduce reported net income due to fair value expensing of options.
- Debt and Liquidity: Confirm the net cash position of approximately $190 million and the current ratio of 4.7 to assess financial flexibility.